Results 211 to 220 of about 26,605 (327)

Efficacy and Safety of Patients With Relapsing Multiple Sclerosis Switching to Ocrelizumab Due to Suboptimal Treatment Response: Results of the 4‐Year CASTING–LIBERTO Trial

open access: yesEuropean Journal of Neurology, Volume 33, Issue 6, June 2026.
ABSTRACT Background Almost 75% of patients with relapsing multiple sclerosis (pwRMS) with suboptimal response to other disease‐modifying therapies (DMTs) showed no evidence of disease activity (NEDA‐3) when treated with ocrelizumab in a large single‐arm multicentre trial over 2 years.
Patrick Vermersch   +14 more
wiley   +1 more source

Skin Boosters: 2026 Updated

open access: yesJournal of Cosmetic Dermatology, Volume 25, Issue 6, June 2026.
ABSTRACT Skin boosters are increasingly used to improve dermal quality through injectable and device‐assisted approaches; however, definitions and clinical evidence remain heterogeneous. Aims To provide an updated overview and propose a practical classification of skin boosters, including mechanisms, delivery methods, clinical outcomes, and limitations.
Kyu‐ho Yi   +7 more
wiley   +1 more source

High Relevance of Fatty Acid Oxidation in a Migrating Mammal, the Nathusius' Pipistrelle (Pipistrellus nathusii)

open access: yesThe FASEB Journal, Volume 40, Issue 10, 31 May 2026.
Bats can sustain powered flight, but their reliance on fatty acid oxidation may limit long‐distance migration compared to birds. Using untargeted metabolomics, we analyzed blood metabolites of Nathusius' pipistrelle under controlled flight and migratory field conditions to identify fuel use.
Alesia Walker   +7 more
wiley   +1 more source

Poster Sessions

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Publication Only

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Home - About - Disclaimer - Privacy